MASLD Screening: Is FIB-4 Missing Too Many Patients With Significant Fibrosis?: Hepatology Communications | September 2026
Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2026
What Did the Study Find?
This prospective study evaluated 186 patients with or at risk for MASLD, using biopsy and/or MRE to identify clinically relevant fibrosis.
- 38% had fibrotic MASLD (≥F2 histology or MRE ≥3.1 kPa).
- FIB-4 ≥1.3 had only 57% sensitivity, meaning 43% of fibrotic cases would never reach second-line testing.
- ELF alone showed moderate discrimination (AUROC 0.77).
- An optimized ELF cutoff of 9.4 provided 80% sensitivity and 65% specificity.
- Lowering ELF thresholds improved sensitivity but markedly reduced specificity.
- Crucially, adding ELF after FIB-4 could not recover patients already excluded by the FIB-4 gatekeeper.
- Concurrent testing—FIB-4 ≥1.3 OR ELF ≥9.4—increased sensitivity to 87%, with 64% specificity.
Why Does It Matter?
Sequential algorithms are only as sensitive as their first gatekeeper. A low FIB-4 may therefore provide false reassurance, particularly when the clinical goal is detecting ≥F2 disease.
GastroAGI Takeaway
The problem may be the pathway, not the second-line test. If ELF is performed only after FIB-4 ≥1.3, nearly half of fibrotic MASLD may never reach further assessment. Concurrent FIB-4 + ELF testing deserves prospective evaluation, particularly in higher-risk populations, before replacing guideline-endorsed sequential algorithms.
